Medical imaging diagnostic equipment field: continuous improvement is worth looking forward to

(
note: 2018, 2019 forecast value)the policy-driven process of localization of medical imaging diagnostic equipment, to promote the growth of China's imaging equipment market size, domestic enterprises in the high-end market breakthrough, import substitution process accelerated. Among them, the rapid development of domestic PET-CT/MRI, import substitution continued to improve, domestic magnetically controlled capsule gastroscope leading foreign enterprises approved for listing in China, in the medical examination and hospital market penetration has a greater room for improvement, domestic in-vascular ultrasound (IVUS) equipment has entered the special examination procedures for innovative medical devices, it is worth looking forward to.PET-CT/PET-MRI PET-CT/PET-MRI is a technique that combines PET (positive electron emission computer fault imaging) with CT and MRI (nuclear magnetic resonance imaging), which provides molecular information such as the detailed function and metabolism of lesions, while CT provides precise anatomical positioning of lesions.Due to the high price and radioactive, before 2018, PET-CT/PET-MRI belongs to Class A large medical equipment, configuration certificate needs to be issued by China's health department, every 5 years planning equipment configuration, and less configuration, therefore, the domestic PET-CT/PET-MRI market is small. In April 2018, the National Health and Wellness Commission released the Large Medical Equipment Configuration License Management Directory (2018), in which PET-CT was moved from Class A equipment to Class B equipment, meaning that PET-CT configuration approval authority is decentralized, the potential demand of hospitals will be released, there is huge room for growth.PET-CT product development is difficult, according to "China's medical equipment development status and trends 2018", 2011-2016, PET-CT market is mainly occupied by GE, Philips, Siemens. With the support of the Ministry of Science and Technology's "12th Five-Year Plan", domestic enterprises represented by United Pictures Medical, Daji Kangming, Andofi Medical, etc. have begun to make breakthroughs in high-end PET-CT products, and the rate of localization has increased significantly in the past two years.According to the Notice of the National Health and Health Commission on the Release of the 2018-2020 Large-scale Medical Equipment Configuration Plan, by the end of 2020, 710 new PET-CT/PET-MRI units will be planned and configured nationwide, with an additional 377 units, or an average of about 126 new units per year in the three years from 2018 to 2020. According to 20 million yuan / Taiwan calculation, the annual market size of about 2.5 billion yuan.Capsule endoscopywas first developed by Israeli scientists in 2000 and has become a first-line diagnosis of small intestine disease after nearly 20 years of development. With the emergence of the new capsule endoscope, the adaptation area of the capsule endoscope has been extended from the small intestine to the esoeso, colon and even the stomach. Traditional capsule endoscopes mainly rely on their own gravity, digestive tract peristaltic or external power system control, random image shooting of the digestive tract, doctors use in-body image recorders and imaging workstations, to understand the subject's entire digestive tract, so as to make a diagnosis of their condition. The above-mentioned examination method is mainly applicable to small intestine examination, is a passive examination method, and can not achieve active control of the capsule endoscope, and therefore does not apply to the larger volume, more shrink lysus, more irregular structure of gastric examination. With its innovative technology of "doing gastroscopy without intitation", magneto-controlled capsule gastroscopy allows endoscopy to expand from targeting patients with obvious clinical symptoms to early diagnosis and screening of healthy populations of potential patients with no obvious symptoms.At present, the domestic capsule endoscope production enterprises are mainly Anhan Technology (Wuhan) Co., Ltd., Chongqing Jinshan Technology (Group) Co., Ltd., Hangzhou Hua Chong Technology Co., Ltd., among them Anhan Technology and Chongqing Jinshan has magnetically controlled capsule gastroscope, competitive.Intravascular ultrasoundintravascular ultrasound (IVUS) is a miniaturized ultrasound device placed in the cardiovascular cavity through a heart catheter, which is mainly used for the diagnosis of coronary system, such as determining the degree of coronary stenosis, plaque properties, immediate implantation effect of postoperative stents, etc.The world's leading manufacturers of IVUS are Vocalno and Boston Scientific, which were acquired by Philips in 2014. IVUS is generally used in perititial coronary artery interventional therapy (PCI), according to the 21st National Forum on Interventional Cardiology (CCIF2018), in 2017 China completed PCI treatment 753,000 cases, the overall uivity of IVUS in China is about 10%, the market size of about 700 million yuan. It is estimated that there are more than 1.5 million cases of PCI space in China, if calculated according to the penetration rate of 20% to 30%, China's IVUS market space will reach 2 billion to 3 billion yuan. In March this year, Shenzhen opened biomedical technology Co., Ltd. IVUS into the special examination procedures for innovative medical devices, indicating that domestic devices have entered this field, the future is worth looking forward to. (Medical Economics)